Experimental Pseudomonas Bacteremia in Neutropenic Rats

Size: px
Start display at page:

Download "Experimental Pseudomonas Bacteremia in Neutropenic Rats"

Transcription

1 ANTIMICROBIAL AGENTs AND CHZMOTHERAPY, OCt. 1976, p Copyright C) 1976 American Society for Microbiology Vol. 10, No. 4 Printed in U.S.A. Synergistic Activity of Carbenicillin and Gentamicin in Experimental Pseudomonas Bacteremia in Neutropenic Rats RITA E. SCOTT AND HUGH G. ROBSON* Division of Infectious Diseases, Departments of Medicine and Microbiology, Royal Victoria Hospital, and Faculty of Medicine,* McGill University, Montreal, Quebec, H3A 2B4 Canada Received for publication 26 May 1976 Rats made neutropenic with cyclophosphamide were infected intraperitoneally with Pseudomonas aeruginosa. The challenge organism was killed synergistically in vitro by the combination of gentamicin and carbenicillin. Untreated neutropenic rats infected with 3 x 106 Pseudomonas died between days 2 and 7, and the overall mortality was 70%. Groups of infected neutropenic rats were treated intramuscularly with 1.5 or 6 mg of gentamicin per kg per dose, 100 or 400 mg of carbenicillin per kg per dose, or 1.5 mg of gentamicin and 100 mg of carbenicillin per kg per dose. Treatment was begun at 2 h postinfection and was continued every 8 h for about 72 h. Cultures of blood and peritoneal washings were performed in control and treated rats at 1, 4, 24, 48, and 72 h postinfection. Gentamicin at either dose level was ineffective in preventing death, but mortality was significantly reduced by high-dose carbenicillin and low-dose combination therapy. In addition, the latter regimens sterilized the peritoneal fluid and blood. Carbenicillin and gentamicin showed in vivo synergy in the treatment of neutropenic Pseudomonas-infected rats. Infections caused by Pseudomonas aeruginosa constitute a serious problem in patients with underlying neoplastic disease (26). The incidence of bacteremic Pseudomonas (refers throughout the text specifically to P. aeruginosa) infection has increased largely due to the aggressive use of potent antineoplastic chemotherapy that may result in prolonged periods of severe neutropenia. Patients colonized with Pseudomonas are at an increased risk of invasive infection during periods of drug-induced neutropenia (23, 24). Antimicrobial therapy of Pseudomonas bacteremia has often proved unsuccessful, and few controlled comparative trials of therapy have been performed in humans (10). Although polymyxin B and sodium colistimethate exhibit in vitro activity against almost all strains ofpseudomonas, they are usually ineffective in the therapy of bacteremic infection, particularly in patients with unremitting neutropenia (26). Gentamicin, also active in vitro against most Pseudomonas isolates, may be similarly ineffective in the neutropenic host with bacteremic infection (4, 5, 21, 25). The introduction of carbenicillin was reported by Bodey et al. to have led to the increased survival of patients with Pseudomonas bacteremia; good results were noted even in patients with persisting neutropenia (6, 7). A 71% complete response rate was reported in a group of 38 patients treated with carbenicillin alone for bacteremic Pseudomonas infection (7). Gentamicin and carbenicillin show antibiotic synergy in vitro against many strains of Pseudomonas (11, 19). This antibiotic combination is frequently employed in the therapy of proven Pseudomonas infection as well as empirically in febrile neutropenic patients prior to the availability of culture results (21). Despite the early institution of combined antibiotic regimens incorporating carbenicillin and gentamicin, the therapy of Pseudomonas bacteremia 646 occurring in a neutropenic host may still fail, particularly if the underlying hematological disease cannot be controlled. In recent studies the successful control of Pseudomonas bacteremia with combination therapy has been reported variously in 33% (23), 60% (27), 62% (22), and 85% of cases (21). Due to the difficulties involved in performing and interpreting trials of antibiotic efficacy in severely ill patients with varying types and degrees of underlying illness, the potential disparity between in vitro and in vivo results, and the potential emergence of Pseudomonas strains resistant to formerly effective agents (12), studies of therapy in appropriate animal models seem justified. Such animal experiments may generate significant data that may be impossible to obtain from studies in humans. The present experiments were designed to

2 VOL. 10, 1976 evaluate the therapeutic efficacy of gentamicin and carbenicillin alone and in combination in experimental Pseudomonas bacteremia in neutropenic rats. A model infection similar to that described by Andriole (1, 2) for nonneutropenic animals was employed; severe neutropenia was induced by the administration of cyclophosphamide. The Pseudomonas strain employed was killed synergistically in vitro by the combination of gentamicin and carbenicillin. Animals treated with a low-dose antibiotic combination showed significantly improved survival as compared with those treated with either gentamicin or carbenicillin in equivalent doses. (This paper was presented in part at the 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., September 1975). MATERIALS AND METHODS Experimental animals. Female, pathogen-free, Sprague-Dawley CFE rats (Carworth Farms, Wilmington, Mass.) weighing 185 to 200 g were used. Induction of neutropenia. Cyclophosphamide (Procytox; Frank W. Horner Ltd., Montreal, Quebec, Canada) was administered intraperitoneally in a dose of 120 mg/kg. The median leukocyte count on days 4 and 5 after cyclophosphamide was approximately 1,000 cells/mm3; on the same days, median neutrophil counts were about 100/mm3. Circulating leukocytes increased by day 6 and reached normal levels by day 10 after injection. No special precautions were taken with the rats during the period of neutropenia, and there were no deaths in neutropenic noninfected rats observed for 15 days. In subsequent experiments neutropenic rats were infected 96 h after the administration of cyclophosphamide. Microorganism and in vitro susceptibility studies. P. aeruginosa 407 was provided by V. T. Andriole, New Haven, Conn. This strain is known to be inhibited synergistically by the combination of gentamicin and carbenicillin (1). The microorganism was lyophilized; for each experiment a fresh vial was used. The synergistic bactericidal activity of the combination of gentamicin and carbenicillin against Pseudomonas 407 was determined in Trypticase soy broth. A 1-ml amount of an overnight broth culture of Pseudomonas 407 was added to 99 ml of broth to give a concentration of about 106 colony-forming units (CFU)/ml. Appropriate antibiotic solutions were added to a series of flasks to produce the following final concentrations (in micrograms per milliliter): gentamicin, 2 or 10; carbenicillin, 25 or 100; a combination of gentamicin, 2, plus carbenicillin, 25; or a combination of gentamicin, 2, plus carbenicillin, 100. Flasks were incubated at 37 C without shaking; at various times after incubation 1-ml portions were removed, and the number of CFU of Pseudomonas was determined in agar pour plates. Synergistic bactericidal activity was defined as a 100-fold increase in killing by the combination as compared ANTIBIOTIC SYNERGY IN PSEUDOMONAS SEPSIS 647 with the most effective single agent after 24 h of incubation. Studies of lethality. Rats were infected intraperitoneally with graded 1.0-ml inocula containing Pseudomonas 407; deaths were scored daily and the animals were observed for 15 days. Commercially supplied gentamicin sulfate (Schering Corporation Ltd., Pointe Claire, Quebec, Canada) and disodium carbenicillin (Ayerst Laboratories, Montreal, Quebec, Canada) were dissolved in water to the required concentration immediately prior to injection. The amounts of drug administered are expressed in milligrams per kilogram per dose. Antibiotic doses were administered by the intramuscular route in volumes of 0.2 ml into the hind limb at 2, 10, 20, 28, 34, 44, 52, 58, and 68 h after bacterial challenge. Attempts were made to alternate injection sites. Doses of the antibiotic combination were administered concurrently, but each agent was injected into a different hind limb. The results were analyzed statistically for significance by the fourfold, chi-square contingency table method. Quantitative bacteriology. Blood was obtained by cardiac puncture from groups of three rats in the different treatment groups at 1, 4, 24, 48, and 72 h after infection. The number of CFU per milliliter of Pseudomonas was determined by incorporating portions of 10-fold dilutions of blood in pour plates. Immediately after blood had been obtained for quantitative culture, the rats were sacrificed and the enumeration of Pseudomonas in the peritoneal cavity was carried out by using the method of Cohn (9). RESULTS Synergistic bactericidal activity in vitro of gentamicin and carbenicillin against Pseudomonas 407. Synergy in vitro was demonstrated for both combinations of gentamicin and carbenicillin against Pseudomonas 407. The flask containing the combination of 2,ug of gentamicin per ml and 100,g of carbenicillin per ml contained no viable organisms at 24- and 48-h incubation periods (Fig. 1). Virulence of Pseudomonas 407 for normal and neutropenic rats. A total of 15 of 20 normal rats infected with 3 x 108 bacteria died of infection (Fig. 2A). All deaths occurred within the first 24 h after bacterial challenge. Smaller inocula were nonlethal for normal rats. Eighteen of twenty neutropenic rats challenged with 3 x 107 organisms died (Fig. 2B). Fourteen of twenty neutropenic rats infected with 3 x 10" Pseudomonas died; all deaths occurred between days 2 and 6 postinfection. Onehalf of the deaths occurred on day 2 postinfection. Only 3 of 20 animals infected with 3 x 105 bacteria died. At autopsy Pseudomonas was recovered from heart blood cultures. Pleural effusions were usually noted, and most spleens contained numerous abscesses of 2 to 3 mm in diameter that yielded Pseudomonas in pure culture.

3 648 SCOTT AND ROBSON 10 -J0 E * - -._.._.._._.. O6 _&~~., GM* p/ 0 4o 2 -' I I $, 4\2* TIME (Hours) FIG. 1. Effect of gentamicin, carbenicillin, and gentamicin-carbenicillin in combination against Pseudomonas 407. Abbreviations: CBN, carbenicillin; GM, gentamicin. 4 cr 0 B LI- D B I 6- INOCULUM A 3,10a A * X105 /~~~~~~~-l X I I * a DAYS POST INFECTION FIG. 2. Cumulative mortality of rats infected intraperitoneally with graded inocula ofpseudomonas 407. Neutropenic rats were injected intraperitoneally 4 days prior to infection with 120 mg of cyclophosphamide per kg. (A) Normal rats; (B) neutropenic rats. The percent mortality of neutropenic rats infected with Pseudomonas was related to the number of organisms employed in the challenge. Neutropenia induced by cyclophosphamide greatly increased the susceptibility of rats to lethal infection. A challenge inoculum of 3 x 10c6 Pseudomonas was employed in the subsequent experiments. Efficacy of antibiotic regimens in neutropenic infected rats. Groups of 30 neutropenic rats received either no therapy, 1.5 or 6 mg ofr gentamicin per kg, 100 or 400 mg of carbenicillin per kg, or a combination of 1.5 mg of gentamicin plus 100 mg of carbenicillin per kg. Twenty-two of thirty neutropenic infectedi control rats (73%) died. Therapy with gentamicin alone was ineffective (Fig. 3A). A total of 24 ANTIMICROB. AGENTS CHEMOTHER. of 30 animals (80%) treated with 1.5 mg of gentamicin per kg and 21 of 30 (70%) treated with 6 mg/kg died, although the deaths were delayed in the group that received high-dose gentamicin therapy. A total of 15 of 30 rats treated with 100 mg of carbenicillin per kg died (Fig. 3B). None of the animals in this treatment group died during the treatment period in the first 3 days after infection. Although the results suggested a beneficial effect of low-dose carbenicillin therapy, this regimen was not significantly better than the control (X2 = 3.45; 0.1 > P > 0.05). A total of 4 of 30 (13%) and 6 of 30 (20%), respectively, animals that received either high-dose carbenicillin or combined lowdose therapy died. Both of these forms of therapy were significantly better than the control (P < 0.01) and also were better than 100 mg of carbenicillin per kg (P < 0.01). No rat treated with high-dose carbenicillin or combined lowdose therapy died during the first 3 days after infection. The results indicate that the combination of carbenicillin and gentamicin exhibited antibiotic synergy both in vitro against Pseudomonas 407 and in vivo against infection caused by this organism in neutropenic animals. Effect of antibiotic regimens on bacteremia and peritoneal lavage cultures. Pseudomonas was present in the blood of untreated animals at 1 h after infection, and the degree of bacteremia rose progressively over the first 24 h of infection (Fig. 4). Too few control animals survived past 24 h to allow later cultures. Bacteremia was detected at some time in all other treatment groups. At 48 and 72 h after infection, rats treated with 100 mg of carbenicillin per kg showed persistent bacteremia of 102 to 80- > A Treatment 0B60~ ~~~AY POS IFECIO B witreatm carbenicillin, 100 mglkg; A, carbenicillin, 400 mg/ kg; or O, carbenicillin, 100 mglkg, and gentamicin, 1.5 mglkg. *, Control untreated rats.

4 VOL. 10, 1976 a 0 o U- Jo 0 Jo ANTIBIOTIC SYNERGY IN PSEUDOMONAS SEPSIS 649 A rats are highly resistant to infection with Pseudomonas 407. In our hands an intraperitoneal inoculum of 3 x 108 organisms caused 70% mortality of control animals within 24 h, but A/ / \ fs smaller inocula were nonlethal. During the period of severe neutropenia 100-fold fewer organisms produced equivalent mortality. Quantitative bacteriological studies in neutropenic infected control rats showed increasing numbers of Pseudomonas in the peritoneum and blood between 4 and 24 h after infection, manifestations of uncontrolled sepsis. Splenic abscesses were noted, indicating the additional presence of multiple parenchymal foci of bacterial proliferation. Native resistance to Pseudomonas in IhItItII 1 healthy individuals, increased susceptibility O during periods of granulocytopenia, and bacter- TIME POST INFECTION (Hours) emic infection with metastatic abscesses are FIG. 4. Qu,antitative blood cultures of neutropenic features of the human interaction with this rats infected intraperitoneally with 3 x 106 Pseudom- pathogen. onas 407. Treeatment groups included: *, untreated Antibiotic therapy was administered early (2 control; A, ccarbenicillin, 100 mglkg: A, carbenicil- h) after the onset of infection, since protective lin, 400 mg/ 'kg; 0, carbenicillin, 100 mglkg, and effects had been previously shown when treatgentamicin, 1.5 mglkg. Values represent the mean of ment was instituted at 2 h, but not when dethree animalsr. layed to 6 h after Pseudomonas 407 infection of nonneutropenic rats (1). The critical impor- 103 CFU/m] 1 of blood. Blood cultures of rats tance of early antibiotic therapy to a successful treated with1400 mg of carbenicillin per kg were outcome in infected neutropenic humans has sterile at 244 and 48 h, although one of three been well documented (21). treated witli this dose was bacteremic at 72 h. Despite a prompt institution of therapy, gen- All blood culitures of rats treated with combined tamicin alone in doses of 1.5 or 6 mg/kg failed to carbenicilln and gentamicin were sterile at z4 h after infection and at later times. Peritoneal lavage cultures correlated well with the degree and persistence of bacteremia (Fig. 5). The number of Pseudomonas present in the peritoneum at zero time (immediately after infection) has been plotted as a theoretic value, assuming complete recovery and viability of the inoculum in the washout fluid. The mean number of CFU recovered from the peritoneum of control rats rose between 4 and 24 h after infection to greater than 104. Peritoneal counts of Pseudomonas diminished progressively in rats treated with 100 mg of carbenicillin per kg, but organisms were recovered at all time intervals. Both 400 mg of carbenicillin per kg and combined carbenicillin-gentamicin regimens sterilized the peritoneal fluid. This effect was observed at 24 h after infection in rats treated with the antibiotic combination and at 48 h in rats treated with high-dose carbenicillin. DISCUSSION There are some important similarities between this model infection and Pseudomonas infection in a human neutropenic host. Normal u< D s D 'La - " TIME POST INFECTION (Hours) FIG. 5. Quantitative cultures of peritoneal washout fluid of neutropenic rats infected intraperitoneally with 3 x 106 Pseudomonas 407. Treatment groups included: 0, untreated control; A, carbenicillin, 100 mg/kg; A, carbenicillin, 400 mg/kg; 0, carbenicillin, 100 mglkg, and gentamicin, 1.5 mg/kg. Values represent the mean of three animals.

5 650 SCOTT AND ROBSON improve the overall survival of neutropenic infected rats. Rats treated with high doses of gentamicin showed short-term benefit only, with no deaths observed during the treatment period, whereas the course of infection was completely unaffected by the lower dose. The reason for the lack of efficacy of gentamicin in the neutropenic rat is not entirely clear and requires further study; however, preliminary data suggest an important pharmacological reason for drug failure in this model. Infected neutropenic rats showed concentrations of detectable gentamicin in serum for only 1.5 to 2 h after an intramuscular dose of 6 mg/kg (R. E. Scott and H. G. Robson, unpublished data). Similar observations were reported by Luft and Kleit; gentamicin was barely detectable in rat sera at 3 h after a single subcutaneous injection of 10 mg/kg (17). The half-life of gentamicin in rat serum was estimated to be about 30 min (17). The failure of gentamicin to cure some patients with Pseudomonas sepsis has also been attributed to inadequate serum and tissue levels that may occur at various times after intermittent drug administration (13, 18). Shorter intervals between doses, larger doses, or the continuous administration of gentamicin as suggested by Bodey et al. (3) may provide improved therapeutic results; such approaches can be assessed using this model. Other factors may also be implicated, however, including antibiotic inactivation by purulent material (8) and deficient phagocytosis and intracellular killing of gentamicin-damaged microorganisms during neutropenia (13). In contrast to gentamicin, carbenicillin in the large dose employed (400 mg/kg) was highly effective. Despite its short duration, this therapeutic regimen significantly reduced mortality, eradicated Pseudomonas from the original peritoneal site of infection, and sterilized the blood. Although the lower dose employed (100 mg/kg) did not significantly reduce eventual mortality, deaths were prevented during therapy, the number of viable Pseudomonas present in the peritoneum was reduced, and the magnitude of bacteremia did not increase between 24 and72 h of infection. The lack of overall benefit of this regimen may be attributable to the eventual multiplication of persisting Pseudomonas when treatment was discontinued, despite survival of the animals to the stage where return of neutrophils to the circulation could be predicted. The effect of more prolonged carbenicillin therapy at the 100-mg/kg dose level remains to be explored. A similar dose response relationship for nonneutropenic rats ANTIMICROB. AGENTS CHEMOTHER. infected with Pseudomonas 407 has been observed (2). Although low-dose gentamicin and carbenicillin regimens were largely ineffective when employed singly, the combination was highly active. We interpret this as evidence of in vivo drug synergy; this phenomenon has previously been documented in nonneutropenic rats (1, 2). Our finding is in agreement with the recent work of Lumish and Norden in a similar neutropenic rat model (Prog. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., 15th, Washington, D.C., Abstr. 201, 1975). These authors also noted the lack of efficacy of gentamicin employed as the sole antimicrobial agent under similar conditions. In another study Saslaw et al. failed to show in vivo synergy in neutropenic monkeys infected with Pseudomonas (20). An equivalent reduction in mortality was observed in rats treated with high-dose carbenicillin, but the effect of the antibiotic combination on bacteremia and peritoneal fluid cultures was even more striking; all cultures were sterile at 24 h and subsequent times. Recent studies by Klastersky et al. have shown that an improvement in response rates of gram-negative infection occurring in patients with neoplasia can be obtained with combinations of antibiotics when the causative agents can be shown to be synergistically inhibited in vitro (14). The number of severely neutropenic patients infected with Pseudomonas was small (14-16); improved survival of this subgroup treated with the carbenicillin-gentamicin combination as compared with either drug alone could not be demonstrated (16). Our studies provide further evidence to support the view that the initial therapy of Pseudomonas sepsis in the neutropenic patient should include both carbenicillin and gentamicin. It will be important to extend these observations to infection in neutropenic rats caused by strains of Pseudomonas that show partial synergy or no synergy in vitro to the carbenicillin-gentamicin combination. The combination has previously been shown to be effective in vivo in nonneutropenic rats infected with a strain of Pseudomonas that showed only partial synergy in vitro (1). This model infection may also prove valuable in assessing the efficacy of agents such as tobramycin, amikacin, and ticarcillin in infections caused by Pseudomonas resistant to carbenicillin or gentamicin. ACKNOWLEDGEMENT We wish to thank Fereshteh Ghadirian and Eva Hawkins for their assistance.

6 VOL. 10, 1976 This research ws supported by Ayerst Laboratories, Montreal, Quebec, Canada. ADDENDUM Since submission of this manuscript, the work of R. M. Lumish and C. W. Norden has been published (J. Infect. Dis. 133: , 1976). LITERATURE CITED 1. Andriole, V. T Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas. J. Infect. Dis. 124(Suppl.):S46-S Andriole, V. T Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin or cephanone combined with tobramycin or gentamicin. J. Infect. Dis. 129: Bodey, G. P., H.-Y. Chang, V. Rodriguez, and D. Stewart Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion. Antimicrob. Agents Chemother. 8: Bodey, G. P., E. Middleman, T. Umsawadi, and V. Rodriguez Infection in cancer patients. Results with gentamicin sulfate therapy. Cancer 29: Bodey, G. P., and V. Rodriguez Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur. J. Cancer 9: Bodey, G. P., V. Rodriguez, and J. K. Luce Carbenicillin therapy of Gram-negative bacilli infections. Am. J. Med. Sci. 257: Bodey, G. P., J. P. Whitecar, E. Middleman, and V. Rodriguez Carbenicillin therapy for Pseudomonas infections. J. Am. Med. Assoc. 218: Bryant, R. E., and D. Hammond Interaction of purulent material with antibiotics used to treat Pseudomonas infections. Antimicrob. Agents Chemother. 6: Cohn, Z. A Determinants of infection in the peritoneal cavity. Yale J. Biol. Med. 35: Davis, S. D., A. Ianetta, and R. J. Wedgewood Antibiotics for Pseudomonas aeruginosa sepsis: inadequate proof of efficacy. (Editorial.) J. Infect. Dis. 124: Eickhoff, T. C In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa. Appl. Microbiol. 18: Greene, W. H., M. Moody, S. Schimpff, V. M. Young, and P. H. Wiernik Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. Ann. Intern. Med. 79: Jackson, G. G., and L. J. Riff Pseudomonas bacteremia: pharmacologic and other bases for failure ANTIBIOTIC SYNERGY IN PSEUDOMONAS SEPSIS 651 of treatment with gentamicin. J. Infect. Dis. 124(Suppl.):S185-S Klastersky, J., R. Cappel, and D. Daneau Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob. Agents Chemother. 2: Klastersky, J., R. Cappel, and D. Daneau Therapy with carbenicillin and gentamicin for patients with cancer and severe infection caused by gramnegative rods. Cancer 31: Klastersky, J., A. Henri, C. Hensgens, and D. Daneau Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. J. Am. Med. Assoc. 227: Luft, F. C., and S. A. Kleit Renal parenchymal accumulation of aminoglycoside antibiotics in rats. J. Infect. Dis. 130: Pennington, J. E., D. C. Dale, H. Y. Reynolds, and J. D. MacLowry Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J. Infect. Dis. 132: Phair, J. P., C. Watanakunakorn, and T. Bannister In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin and the combination of carbenicillin and gentamicin. Appl. Microbiol. 18: Saslaw, S., H. N. Carlisle, and M. Moheimani Comparison of gentamicin, carbenicillin and gentamicin, and carbenicillin in Pseudomonas sepsis in monkeys. Antimicrob. Agents Chemother. 3: Schimpff, S., W. Satterlee, V. M. Young, and A. Serpick Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N. Engl. J. Med. 284: Schimpff, S. C., W. H. Greene, V. M. Young, and P. H. Wiernik Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur. J. Cancer 9: Schimpff, S. C., W. H. Greene, V. M. Young, and P. H. Wiernik Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J. Infect. Dis. 130(Suppl):S24-S Schimpff, S. C., V. M. Young, W. H. Greene, G. D. Vermeulen, M. R. Moody, and P. H. Wiernik Origin of infection in acute non-lymphocytic leukemia. Ann. Intern. Med. 77: Tapper, M. L., and D. Armstrong Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. J. Infect. Dis. 130(Suppl.):S14-S Whitecar, J. P., Jr., M. Luna, and G. P. Bodey Pseudomonas bacteremia in patients with malignant disease. Am. J. Med. Sci. 260: Young, L. S Gentamicin: clinical use with carbenicillin and in-vitro studies with recent isolates of Pseudomonas aeruginosa. J. Infect. Dis (Suppl.):S202-S206.

Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model

Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model Journal of Antimicrobial Chemotherapy (1985) 15, Suppl. A, 313-321 Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model Joyce J.

More information

Comparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae

Comparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Oct. 1976, P. 592-597 Copyright 1976 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Comparative Activity of Netilmicin, Gentamicin, Amikacin, and

More information

Staphylococcus aureus

Staphylococcus aureus ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, OCt. 1981, p. 463-469 0066-4804/81/100463-07$02.00/0 Vol. 20, No. 4 In Vitro and In Vivo Studies of Three Antibiotic Combinations Against Gram-Negative Bacteria and

More information

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys ANTIbMCROBIAL AGENTS AND CHEMOTHERAPY, June 197, p. 460-465 Copyright 197 American Society for Microbiology Vol. 1, No. 6 Printed in U.S.A. Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal

More information

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY

More information

Antibiotics in Gram-Negative Infections

Antibiotics in Gram-Negative Infections ANTIMICOBIAL AGENTS AND CHEMOTHEAPY, Dec. 1972, p. 470-475 Copyright 1972 American Society for Microbiology Vol. 2, No. 6 Printed in U.S.A. Clinical Significance of In Vitro Synergism Between Antibiotics

More information

F and therapeutic problem in patients with

F and therapeutic problem in patients with MANAGEMENT OF FEVE OF UNKNOWN OIGIN IN PATIENTS WITH NEOPLASMS AND NEUTOPENIA VICTOIO ODIGUEZ, MD, MICHAEL BUGESS, AND GEALD P. BODEY, MD* MD, During 81 -febrile episodes, 76 cancer patients with neutropenia

More information

Pharmacological Evaluation of Amikacin in Neonates

Pharmacological Evaluation of Amikacin in Neonates ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.

More information

Therapy of Staphylococcal Infections in Monkeys

Therapy of Staphylococcal Infections in Monkeys APuPED MICROBIOLOGY, Mar. 1971, P. 440-446 Copyright 1971 American Society for Microbiology Vol. 21, No. 3 Printed in U.S.A. Therapy of Staphylococcal Infections in Monkeys VI. Comparison of Clindamycin,

More information

Synergy Between Cephalosporin and Aminoglycoside

Synergy Between Cephalosporin and Aminoglycoside ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1974, P. 571--577 Copyright 0 1974 American Society for Microbiology Vol. 5, No. 6 Printed in U.S.A. Synergy Between Cephalosporin and Aminoglycoside Antibiotics

More information

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious

More information

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage

An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",

More information

Persistent in Kidneys

Persistent in Kidneys ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1981, p. 381-385 0066-4804/81/030381-05$02.00/0 Vol. 19, No. 3 Prevention of Acute and Chronic Ascending Pyelonephritis in Rats by Aminoglycoside Antibiotics

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

Antibiotic-Resistant Bacteria in Surveillance Stool Cultures of

Antibiotic-Resistant Bacteria in Surveillance Stool Cultures of ANTIMICROBIAI AGENTS AND CHEMOTHERAPY, Sept. 1986, p. 435-439 0066-4804/86/090435-05$0)2.00/0 Copyright 1986. American Society for Microbiology Vol. 30, No. 3 Antibiotic-Resistant Bacteria in Surveillance

More information

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

More information

Granulocytopenic Cancer Patients

Granulocytopenic Cancer Patients ANTIMICROBIL AGZNTS AND CHzMOTHzRAPY, Nov. 1977, p. 618-624 Copyright 0 1977 American Society for Microbiology Vol. 12, No. 5 Printed in U.S.A. Amikacin and Cephalothin: Empiric Regimen for Granulocytopenic

More information

Emergence of Gentamicin- and Carbenicillin-Resistant Pseudomonas aeruginosa in a Hospital Environment

Emergence of Gentamicin- and Carbenicillin-Resistant Pseudomonas aeruginosa in a Hospital Environment ANTImICROBsuL AGENTS AND CHEMOTHERAPY, Mar. 1976, p. 474-48 Copyright 1976 American Society for Microbiology Vol. 9, No. 3 Printed in U.S.A. Emergence of Gentamicin- and Carbenicillin-Resistant Pseudomonas

More information

Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P

Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P Table 1. IDsos of the test antibiotics against each strain of bacterium Fig. 2. Synergy

More information

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD

More information

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

Antibiotic Susceptibility of Pseudomonas aeruginosa

Antibiotic Susceptibility of Pseudomonas aeruginosa ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1978, p. 979-984 0066-4804/78/0013-0979$02.00/0 Copyright ) 1978 American Society for Microbiology Vol. 13, No. 6 Printed in U.S.A. Effect of Triethylenetetramine

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

Reducing Infections in Surgical Practice. Fred A Sweet, MD Rockford Spine Center Illinois, USA

Reducing Infections in Surgical Practice. Fred A Sweet, MD Rockford Spine Center Illinois, USA Reducing Infections in Surgical Practice Fred A Sweet, MD Rockford Spine Center Illinois, USA Introduction: How bacteria get in The Host The Surgeon The Procedure The STAFF Skin PREP Prophylactic Antibiotics

More information

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* 44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine

More information

Responsiveness of Experimental Surgical-Wound Infections

Responsiveness of Experimental Surgical-Wound Infections ANTIMICROBIAL AGENTS AND CHZMOTHERAPY, JUlY 1976, P. 45-51 Copyright C 1976 American Society for Microbiology Vol. 10, No. 1 Printed in U.S.A. Responsiveness of Experimental Surgical-Wound Infections to

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005 .'URRENT THERAPEUTIC RESEA VOLUME 66, NUMBER 3, MAY/JuNE 2005 Efficacy of Moxifloxacin Monotherapy Versus Gatifloxacin Monotherapy, Piperacillin- Tazobactam Combination Therapy, and Clindamycin Plus Gentamicin

More information

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats THE JOURNAL OF INFECTIOUS DISEASES VOL. 124, SUPPLEMENT DECEMBER 1971 1971 by the University of Chicago. All rights reserved. Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats J. Allan Wait,

More information

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry

More information

Patients. Excludes paediatrics, neonates.

Patients. Excludes paediatrics, neonates. Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All

More information

available. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory

available. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory ANTimICROBIAL AGENTh AND CHEMOTHERAPY, OCt. 1976, p. 677-681 Copyright 1976 American Society for Microbiology Vol. 10, No. 4 Printed in U.S.A. In Vitro Susceptibility of Gentamicin-Resistant Enterobacteriaceae

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method

Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Journal of Antimicrobial Chemotherapy (1988) 22, 23-33 Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Barforo Isaksson'*, Lennart Nibson*, Rolf Mailer' and

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to

More information

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.

More information

The Inpatient Management of Febrile Neutropenia

The Inpatient Management of Febrile Neutropenia UCSF Medical Center Adult Blood and Marrow Transplant Program 400 Parnassus Avenue, San Francisco, CA 94143 SOP # CL 120.05 The Inpatient Management of Febrile Neutropenia BACKGROUND: Neutropenia results

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

Discrepancy Between Carbenicillin and Ampicillin Activities Against Enterococci and Listeria

Discrepancy Between Carbenicillin and Ampicillin Activities Against Enterococci and Listeria ANTMCROBAL AGENTS AND CHEMOTHEAPY, Mar. 193, p. 3339 Copyright 193 American Society for Microbiology Vol. 3, No. 3 Printed in U.S.A. Discrepancy Between Carbenicillin and Ampicillin Activities Against

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA

IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of

More information

Received 8 April 2012; received in revised form 15 December 2012; accepted 28 December 2012

Received 8 April 2012; received in revised form 15 December 2012; accepted 28 December 2012 Journal of Infection and Public Health (2013) 6, 216 221 Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos

More information

Aminoglycoside-resistant enterococci

Aminoglycoside-resistant enterococci Aminoglycoside-resistant enterococci M. J. BASKER, B. SLOCOMBE, AND R. SUTHERLAND From Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey J. clin. Path., 1977, 30, 375-380 SUMMARY

More information

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

Central Nervous System Infections

Central Nervous System Infections Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY

More information

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although

More information

NAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE. J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE and G. H.

NAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE. J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE and G. H. 46 THE JOURNAL OF ANTIBIOTICS APR. 1976 NAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE a G. H. WARREN Research Division, Wyeth Laboratories,

More information

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified

More information

Effeet on Bacterial Growth

Effeet on Bacterial Growth ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 17, p. 36-366 Copyright ( 17 American Society for Microbiology Vol., No. 5 Printed in U.S.A. Automatic Radiometric Measurement of Antibiotic Effeet on Bacterial

More information

Sepsis is the most common cause of death in

Sepsis is the most common cause of death in ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10999/033/001A Case No: 7006569 The in exercise of the powers conferred on it by Animal Remedies

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin

More information

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007 GeNei Bacterial Antibiotic Sensitivity Teaching Kit Manual Cat No. New Cat No. KT68 106333 Revision No.: 00180705 CONTENTS Page No. Objective 3 Principle 3 Kit Description 4 Materials Provided 5 Procedure

More information

EXCEDE Sterile Suspension

EXCEDE Sterile Suspension VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free

More information

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3

More information

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

Mono- versus Bitherapy for Management of HAP/VAP in the ICU Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acecare 2mg/ml Solution for Injection for Dogs and Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains

More information

Treatment of Gram-negative infections in patients before and after

Treatment of Gram-negative infections in patients before and after Postgrad. med. J. (April 1969) 45, 254-260. Treatment of Gram-negative infections in patients before and after renal transplantation Summary Sixty-six Gram-negative infections, occurring in thirty-four

More information

Some Antibacterial Agents Used with Koi (oz refers to weight unless otherwise specified)

Some Antibacterial Agents Used with Koi (oz refers to weight unless otherwise specified) Some Antibacterial Agents Used with Koi (oz refers to weight unless otherwise specified) (Note: many chemicals have been used at one time or another to combat bacterial disease in koi. We have attempted

More information

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:

More information

ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis

ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis GDR11136 ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis February 2012 Summary The challenge data presented in this technical bulletin was completed

More information

Comparison of Efficacies of Oral Levofloxacin and Oral Ciprofloxacin in a Rabbit Model of a Staphylococcal Abscess

Comparison of Efficacies of Oral Levofloxacin and Oral Ciprofloxacin in a Rabbit Model of a Staphylococcal Abscess ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1999, p. 667 671 Vol. 43, No. 3 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of Efficacies of Oral

More information

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED

More information

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health

More information

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS 390 CHEMOTHERAPY JULY 1967 GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS M. OHOKOSHI*, Y. NAIDE, T. KAWAMURA, K. SUZUKI,

More information

UCSF Medical Center Guidelines for Inpatient Management of Febrile Neutropenia

UCSF Medical Center Guidelines for Inpatient Management of Febrile Neutropenia Published on Infectious Diseases Management Program at UCSF (https://idmp.ucsf.edu) Home > UCSF Medical Center Guidelines for Inpatient Management of Febrile Neutropenia UCSF Medical Center Guidelines

More information

EPAR type II variation for Metacam

EPAR type II variation for Metacam 23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents

More information

Drug resistance in relation to use of silver sulphadiazine cream in a burns unit

Drug resistance in relation to use of silver sulphadiazine cream in a burns unit J. clin. Path., 1977, 30, 160-164 Drug resistance in relation to use of silver sulphadiazine cream in a burns unit KIM BRIDGES AND E. J. L. LOWBURY From the MRC Industrial Injuries and Burns Unit, Birmingham

More information

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis

More information

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase

More information

Tobramycin. Received for publication 5 December 1974

Tobramycin. Received for publication 5 December 1974 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 75, P. -29 Copyright 75 American Society for Microbiology Vol. 8, No. 1 Printed in U.S.A. Therapy of Pseudomonas aeruginosa Infections with Tobramycin DONALD

More information

Inactivation of Burkholderia mallei in equine serum for laboratory use.

Inactivation of Burkholderia mallei in equine serum for laboratory use. JCM Accepted Manuscript Posted Online 11 February 2015 J. Clin. Microbiol. doi:10.1128/jcm.03141-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13

More information

Combination vs Monotherapy for Gram Negative Septic Shock

Combination vs Monotherapy for Gram Negative Septic Shock Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,

More information

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy

Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1

More information

GARY WOODNUTT* AND VALERIE BERRY SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania

GARY WOODNUTT* AND VALERIE BERRY SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1999, p. 29 34 Vol. 43, No. 1 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Two Pharmacodynamic Models for Assessing

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle

More information

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0

More information

Synergism Between Penicillin, Clindamycin, or Metronidazole and Gentamicin Against Species of the Bacteroides melaninogenicus and

Synergism Between Penicillin, Clindamycin, or Metronidazole and Gentamicin Against Species of the Bacteroides melaninogenicus and ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1984, p. 71-77 0066-4804/84/010071-07$02.00/0 Copyright C 1984, American Society for Microbiology Vol. 25, No. 1 Synergism Between Penicillin, Clindamycin, or

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information